Impact of Non-Alcoholic Fatty Liver Disease on COVID-19 Severity and Healthcare Outcomes: A Systematic Review
Abstract
The systematic review investigated the association between non-alcoholic fatty liver disease (NAFLD) and COVID-19, focusing on pathophysiology, clinical outcomes, and public health implications. A comprehensive search of EBSCO, Scopus, and PubMed from January 2020 to December 2022 was conducted, following PRISMA guidelines. Included studies involved patients diagnosed with NAFLD or metabolic-associated fatty liver disease (MAFLD) and reported relevant comorbidities and COVID-19 outcomes. Quality was assessed using tools like the Newcastle-Ottawa Scale and AMSTAR-2. The review found that COVID-19 patients with NAFLD often had multiple comorbidities, especially diabetes and cardiovascular disease, which worsened outcomes. NAFLD was linked to higher hospitalization rates (odds ratio ~3.25), longer hospital stays by about two days, increased oxygen supplementation, higher ICU admissions, and a trend toward increased mortality, though mortality significance varied. Liver injury, indicated by elevated ALT and AST levels and hepatic steatosis on imaging, correlated with severe COVID-19. NAFLD patients showed systemic inflammation, immune dysregulation, and coagulation abnormalities contributing to disease severity. Ethnic disparities were noted, with certain groups having higher NAFLD prevalence and worse COVID-19 outcomes. These findings reveal challenges for healthcare systems due to increased resource demands and the need for integrated liver function monitoring during COVID-19 care. Overall, NAFLD significantly impacts COVID-19 severity through complex metabolic and immunological pathways, emphasizing the importance of clinical vigilance and multidisciplinary management for this high-risk population.
Downloads
References
Chang, Y., Jeon, J., Song, T. J., & Kim, J. (2022). Association between the fatty liver index and the risk of severe complications in COVID-19 patients: A nationwide retrospective cohort study. BMC Infectious Diseases, 22(1), 384.
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., … Zhang, L. (2021). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. The Lancet, 395(10223), 507–513.
Du, M., Yang, S., Liu, M., & Liu, J. (2022). COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms. Clinics and Research in Hepatology and Gastroenterology, 46(2), 101793.
Fan, Z., Chen, L., Li, J., Cheng, X., Yang, J., Tian, C., … Zhang, F. (2020). Clinical features of COVID-19-related liver functional abnormality. Clinical Gastroenterology and Hepatology, 18(7), 1561–1566.
Hashemi, S. M. A., Thijssen, M., Hosseini, S. Y., Tabarraei, A., Pourkarim, M. R., & Sarvari, J. (2021). Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. Archives of Virology, 166(8), 2089-2108.
Hussain, A., Bhowmik, B., & do Vale Moreira, N. C. (2020). COVID-19 and diabetes: Knowledge in progress. Diabetes Research and Clinical Practice, 162, 108142.
Jafarzadeh, A., Jafarzadeh, S., Nozari, P., Mokhtari, P., & Nemati, M. (2021). Lymphopenia an important immunological abnormality in patients with COVID‐19: Possible mechanisms. Scandinavian Journal of Immunology, 93(2), e12967.
Jeeyavudeen, M. S., Chaudhari, R., Pappachan, J. M., & Fouda, S. (2023). Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease. World Journal of Gastroenterology, 29(3), 487.
Ji, D., Qin, E., Xu, J., Zhang, D., Cheng, G., Wang, Y., … Wei, X. (2020). Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. Journal of Hepatology, 73(2), 451–453.
Kumar, R., Porwal, Y. C., Dev, N., Kumar, P., Chakravarthy, S., & Kumawat, A. (2020). Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. Journal of Family Medicine and Primary Care, 9(1), 390–394.
Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., … Zelber-Sagi, S. (2022). Advancing the global public health agenda for NAFLD: A consensus statement. Nature Reviews Gastroenterology & Hepatology, 19(1), 60–78.
Lei, P., Zhang, L., Han, P., Zheng, C., Tong, Q., Shang, H., … Song, Y. (2020). Liver injury in patients with COVID-19: Clinical profiles, CT findings, the correlation of the severity with liver injury. Hepatology International, 14(5), 733–742.
Montori, M., Baroni, G. S., Santori, P., Di Giampaolo, C., Ponziani, F., Abenavoli, L., & Scarpellini, E. (2023). Liver damage and COVID-19: At least a “two-hit” story in systematic review. Current Issues in Molecular Biology, 45(4), 3035–3047.
Nafakhi, H., Alareedh, M., Al-Buthabhak, K., Shaghee, F., Nafakhi, A., & Kasim, S. (2021). Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(1), 33–38.
Parlak, A. E., Toslak, I. E., & Selcuk, N. T. (2025, June). Can opportunistic use of computed tomography help reveal the association between hepatic steatosis and disease severity in hospitalized COVID-19 patients? RöFo, 197, (06), 648–656).
Prins, G. H., & Olinga, P. (2020). Potential implications of COVID‐19 in non‐alcoholic fatty liver disease. Liver International, 40(10), 2568.
Robea, M. A., Balmus, I. M., Girleanu, I., Huiban, L., Muzica, C., Ciobica, A., … Trifan, A. (2023). Coagulation dysfunctions in non-alcoholic fatty liver disease—Oxidative stress and inflammation relevance. Medicina, 59(9), 1614.
Sharma, A., Jaiswal, P., Kerakhan, Y., Saravanan, L., Murtaza, Z., Zergham, A., … Malik, P. (2021). Liver disease and outcomes among COVID-19 hospitalized patients–a systematic review and meta-analysis. Annals of Hepatology, 21, 100273.
Vrsaljko, N., Samadan, L., Viskovic, K., Mehmedović, A., Budimir, J., Vince, A., & Papic, N. (2022). Association of nonalcoholic fatty liver disease with COVID-19 severity and pulmonary thrombosis: CovidFAT, a prospective, observational cohort study. Open Forum Infectious Diseases, 9(4) 1–8.
World Health Organization. (2020). Coronavirus disease (COVID-19) pandemic. https://www.who.int/health-topics/coronavirus
Yip, T. C. F., Lui, G. C. Y., Wong, V. W. S., Chow, V. C. Y., Ho, T. H. Y., Li, T. C. M., … Wong, G. L. H. (2021). Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut, 70(4), 733–742.
Zhang, R., Wang, Q., & Yang, J. (2022). Impact of liver functions by repurposed drugs for COVID-19 treatment. Journal of Clinical and Translational Hepatology, 10(4), 748.
Zhang, S., Wang, Z., Chang, R., Wang, H., Xu, C., Yu, X., … Cai, Y. (2020). COVID-19 containment: China provides important lessons for global response. Frontiers of Medicine, 14(2), 215–219.
